---
figid: PMC3474103__bjr-85-682-g022
figtitle: Diagram demonstrating the sites and mechanism of action of novel agents
  for the management of pancreatic endocrine neoplasm
organisms:
- Dipturus trachyderma
- Homo sapiens
organisms_ner:
- Homo sapiens
- Drosophila melanogaster
pmcid: PMC3474103
filename: bjr-85-682-g022.jpg
figlink: /pmc/articles/PMC3474103/figure/bjr-85-682-g022/
number: F22
caption: Diagram demonstrating the sites and mechanism of action of novel agents for
  the management of pancreatic endocrine neoplasm. The growth factor receptors when
  occupied by their respective growth factors (in an autocrine or paracrine manner)
  lead to autophosphorylation of the intracellular tyrosine kinase component of the
  receptor. This activates the mammalian target of rapamycin (mTOR) pathway (among
  others), ultimately promoting protein synthesis, cell cycle progression and cell
  survival. The pathway can be inhibited by monoclonal antibodies to growth factor
  receptors, tyrosine kinase inhibitors or downstream mTOR inhibitors.
papertitle: 'Pancreatic endocrine neoplasms: a current update on genetics and imaging.'
reftext: S Philips, et al. Br J Radiol. 2012 Jun;85(1014):682-696.
year: '2012'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.8724013
figid_alias: PMC3474103__F22
figtype: Figure
redirect_from: /figures/PMC3474103__F22
ndex: 588a4b44-deb0-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3474103__bjr-85-682-g022.html
  '@type': Dataset
  description: Diagram demonstrating the sites and mechanism of action of novel agents
    for the management of pancreatic endocrine neoplasm. The growth factor receptors
    when occupied by their respective growth factors (in an autocrine or paracrine
    manner) lead to autophosphorylation of the intracellular tyrosine kinase component
    of the receptor. This activates the mammalian target of rapamycin (mTOR) pathway
    (among others), ultimately promoting protein synthesis, cell cycle progression
    and cell survival. The pathway can be inhibited by monoclonal antibodies to growth
    factor receptors, tyrosine kinase inhibitors or downstream mTOR inhibitors.
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - ANGPT1
  - ANGPT2
  - ANGPT4
  - AREG
  - BDNF
  - CSF1
  - EFNA1
  - EFNA2
  - EFNA3
  - EFNA4
  - EFNA5
  - EGF
  - EREG
  - FGF1
  - FGF10
  - FGF16
  - FGF17
  - FGF18
  - FGF19
  - FGF2
  - FGF20
  - FGF21
  - FGF22
  - FGF23
  - FGF3
  - FGF4
  - FGF5
  - FGF6
  - FGF7
  - FGF8
  - FGF9
  - FLT3LG
  - HGF
  - IGF1
  - IGF2
  - INS
  - KITLG
  - NGF
  - NTF3
  - NTF4
  - PDGFA
  - PDGFB
  - PDGFC
  - PDGFD
  - PGF
  - TGFA
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - EGFR
  - KDR
  - FLT1
  - FLT4
  - PDGFRB
  - PDGFRA
  - KIT
  - RAF1
  - RNASE3
  - ABL1
  - MTTP
  - DSP-AS1
  - ABL2
  - MTOR
  - RRAD
  - Egfr
  - Pvr
  - blo
  - Raf
  - Abl
  - Abi
  - Mtor
  - Tor
  - rad
  - pins
  - pre-mod(mdg4)-AD
  - Temsirolimus
  - Tyrosine
  - tyrosine
  - Rapamycin
  - Sirolimus
  - Cancer
---
